Published in PLoS One on March 29, 2016
Quantifying heterogeneity in a meta-analysis. Stat Med (2002) 83.16
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med (1998) 32.43
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med (2003) 14.40
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res (2011) 13.63
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol (2010) 11.77
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J (2011) 8.96
Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol (2001) 7.46
Matching using estimated propensity scores: relating theory to practice. Biometrics (1996) 6.73
A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med (2007) 6.48
Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat (2012) 5.35
The design of simulation studies in medical statistics. Stat Med (2006) 5.30
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet (2009) 5.30
Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med (2012) 4.69
Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J (2012) 4.62
The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med (2012) 3.35
Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials (2005) 3.19
Public health. Responding to market failures in tuberculosis control. Science (2001) 3.12
A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol (2002) 2.57
Rational use of moxifloxacin for tuberculosis treatment. Lancet Infect Dis (2011) 2.21
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother (2006) 2.14
European union standards for tuberculosis care. Eur Respir J (2012) 1.73
Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med (2007) 1.46
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies. Stat Med (2009) 1.27
The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med (1997) 1.27
Systematic review of methods for individual patient data meta- analysis with binary outcomes. BMC Med Res Methodol (2014) 1.17
Clarithromycin is inactive against Mycobacterium tuberculosis. Antimicrob Agents Chemother (1995) 1.12
Propensity score matching in randomized clinical trials. Biometrics (2010) 0.92
A comparison of marginal odds ratio estimators. Stat Methods Med Res (2016) 0.90
Fluoroquinolones for treating tuberculosis (presumed drug-sensitive). Cochrane Database Syst Rev (2013) 0.89
Comparative safety of the different macrolides. Int J Antimicrob Agents (2001) 0.87
Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach. Curr Pharm Des (2011) 0.86
Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med (2012) 4.69
Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J (2012) 3.00
Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. Clin Infect Dis (2016) 0.86
Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J (2017) 0.75